Click and hear Paul G. Richardson present the data for the combination therapy with elotuzumab in combination pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. Elotuzumab, an immunostimulatory monoclonal antibody targeting SLAMF7, enables selective killing of MM cells through multiple mechanisms of action and synergizes with the immunomodulatory drug pomalidomide. This study demonstrated sustained and clinically relevant PFS and OS benefits for elotuzumab plus pomalidomide and dexamethasone vs pomalidomide in combination with dexamethasone, with no new safety signals. These data support the long-term favorable efficacy–safety profile of elotuzumab plus pomalidomide and dexamethasone and suggest this regimen could be considered as a standard of care for patients with relapsed/refractory multiple myeloma after failure of lenalidomide and a proteasome inhibitor.

Despite recent advances in MM therapy, the disease remains incurable. Patients with late-stage RRMM refractory to pomalidomide and/or daratumumab have limited effective treatment options. Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in multiple myeloma. In this MEDtalk Paul G. Richardson present updated efficacy and safety of melflufen + low-dose dexamethasone in patients refractory to pomalidomide and/or daratumumab (HORIZON-study).

The SAM domain and HD domain 1 (SAMHD1) protein is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, which has been initially described to restrict human immunodeficiency virus type 1 (HIV-1) in the immune cells. This study shows that SAMHD1 is expressed in approximately half of de novo diffuse large B-cell Lymphomas at a variable level and correlates with cell of origin (GC), biomarkers of tumor aggressiveness (eg MYC, proliferation) and clinical outcome.

Katsotuimmat MEDtalk-videot

ASCO 2019: Progress in treatment of inherited cancer   Katso video

ASCO 2019: Progress in treatment of inherited cancer

<script src="https://fast.wistia.com/embed/medias/4rwno0og6n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4rwno0og6n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4rwno0og6n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Progress in treatment of inherited cancer&nbsp;&nbsp;&nbsp;<a href='https://bestprac.fi/webinar/asco-2019-progress-in-treatment-of-inherited-cancer/'>Katso video
ASCO 2019: Progress in treatment of inherited cancer

Metastasoituneen ei-pienisoluisen keuhkosyövän ensilinjan hoito – immuno-onkologian rooli vuonna 2019

<img width="600" height="360" src="https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-600x360.png" class="attachment-category_newDes_thumb_1 size-category_newDes_thumb_1 wp-post-image" alt="" srcset="https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-600x360.png 600w, https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-300x179.png 300w, https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-768x459.png 768w, https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-1024x612.png 1024w, https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-90x54.png 90w, https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap-360x215.png 360w, https://bestprac.fi/wp-content/uploads/sites/4/2019/06/jussi-koivunen_playknap.png 1200w" sizes="(max-width: 600px) 100vw, 600px" />
Metastasoituneen ei-pienisoluisen keuhkosyövän ensilinjan hoito – immuno-onkologian rooli vuonna 2019&nbsp;&nbsp;&nbsp;<a href='https://bestprac.fi/webinar/metastasoituneen-ei-pienisoluisen-keuhkosyovan-ensilinjan-hoito-immuno-onkologian-rooli-vuonna-2019/'>Katso video
Metastasoituneen ei-pienisoluisen keuhkosyövän ensilinjan hoito – immuno-onkologian rooli vuonna 2019

In this MEDtalk Stine Mikkelsen present the first study investigating submicroscopic copy number variations/ uniparental disomy in idiopathic cytopenia of undetermined significance patients. In a subset of patients with otherwise no detectable genetic abnormalities, Stine Mikkelsen and colleagues identified structural variations involving genes recurrently affected in MDS. Their results suggest that SNP-A can aid the prognostics of ICUS patients by identifying submicroscopic structural variations as risk markers for poor OS.

TOURMALINE-MM3 is a phase 3, double-blind, placebo-controlled study, where ixazomibimproved PFS, and is the first study to evaluate the impact ofmaintenance therapyon quality of life in postautologous stem cell transplant in newly diagnosed multiple myeloma. In this MEDtalkFredrik Schjesvoldpresent the data from the study showing, that active treatment with ixazomibdid not have an adverse impact on HRQoL.

The Nordic Myeloma Study Group (NMSG) initiated the CARFI trial, an open randomized phase II study, to investigate the efficacy and safety of carfilzomib as part of induction and conditioning in salvage ASCT and to evaluate the role of carfilzomib/dexamethasone maintenance after salvage ASCT. In this MEDtalk Henrik Gregersen report that maintenance therapy with carfilzomib and dexamethasone maintenance prolongs median time to progression with approximately 6 months following salvage ASCT in multiple myeloma.

#Tuorein julkaisu

Onkologia / hematologia

Nro. 30 • huhtikuu 2019
8. vuosikerta
  • iCAN
  • Tupakka ja syöpä
  • Waldenströmin makroglobulinemia

EHA 2019

ASCO 2019

ASH 2018

#

Onkologia ja Hematologia

Heikki Minn,

Heikki Minn,
professori

Taina Turpeenniemi-Hujanen,

Taina Turpeenniemi-Hujanen,
professori, ylilääkäri

Vesa Kataja,

Vesa Kataja,
dosentti, johtajaylilääkäri